Month: March 2023

       Press release – Friday 24th March 2023 – 08h45 AM General Meeting ARGAN – 23th March 2023    Dividend 2022 : €3/share (+ 15%) with the option for the payment of the dividend in shares The general meeting of ARGAN’s shareholders was held on Thursday 23 March 2023 at the Salons Hoche in Paris. The total number of existing shares was 22,981,364 for a total number of voting rights of 22,969,305. At this General Meeting, the shareholders present, duly represented, having validly given proxy to the Chairman or voted by correspondence, together held 18,261,745 shares and as many voting rights, i.e. 79.5% of the total. The Combined General Meeting of Shareholders approved all the proposed resolutions, including : – Resolution No. 4 providing for the distribution of a dividend of €3/share – Resolution n°5 proposing...

SOGECLAIR will change its governanceSeparation of the functions of Chairman of the Board of Directors and Chief Executive Officer at the close of the General Meeting of May 11, 2023 Philippe Robardey will assume the function of Chairman of the Board of Directors Olivier Pedron, current Chief Operating Officer of SOGECLAIR, will be appointed Chief Executive OfficerBlagnac, March 24, 2023, SOGECLAIR, supplier of innovative solutions with high added value for a safer and less-consuming mobility, announces that the Board of Directors of March 22, 2023 has decided to modify the structure of governance and to opt for a dissociation of the functions of Chairman of the Board of Directors from those of the General Management at the end of the General Meeting of May 11, 2023. This change in governance will enable growth to continue and is part...

Announcement no. 6 2023 Copenhagen – 24 March 2023 – Agillic A/S (Nasdaq First North Growth Market Denmark: AGILC) completes the registration of 801,085 new shares. In connection with the transaction that was announced on 14 March 2023, the Board of Directors hereby announces that the Company has completed and registered with the Danish Business Authority the share capital increase of a nominal value of DKK 80,108.50 (801,085 shares of DKK 0.10 each) (the “New Shares”), representing 7.81% of the registered share capital of the Company prior to the capital increase and 7.24% of the share capital following the share capital increase. The New Shares are expected to be admitted to trading and official listing under the permanent ISIN code DK0060955854 on Nasdaq First North Copenhagen A/S with effect from 28 March 2023. After registration...

Date: 2 Release: Before opening of Euronext Please open the following link to read the full report including annexes:AttachmentFULL PRESS RELEASE

Enefit Green will change the disclosure date of the interim report for the first quarter of 2023. According to previously reported information, the first quarter 2023 interim report was expected to be published on 4 May 2023. The new disclosure date for first quarter 2023 interim report is 5 May 2023.Further information: Sven Kunsing Head of Finance Communicationsinvestor@enefitgreen.eehttps://enefitgreen.ee/en/investorile/ Enefit Green is one of the leading diversified renewable energy producers in the Baltic Sea area. The Company wind farms in Estonia and Lithuania, cogeneration plants in Estonia and Latvia, solar farms in Estonia and Poland, a pellet plant in Latvia and a hydroelectric plant in Estonia. In addition, the Company is developing several wind and solar farms in the mentioned countries and Finland. As of the end of 2021,...

Oslo, 24 March 2023: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that the Board of Directors of Ultimovacs ASA has approved the Annual Report and ESG Report for 2022. Please find a PDF version of the annual report, as well as the report in European Single Electronic Format (ESEF), as attachments to this release. The Annual Report is also available at the company’s website: www.ultimovacs.com This information is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act. For further information, please see www.ultimovacs.com or contact: Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA Email: je@radforsk.no Phone: +47 480 96 355 Carlos de Sousa, CEO Email: carlos.desousa@ultimovacs.com Phone:...

STOCKHOLM, SWEDEN – March 24, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2022. The report is now available to download at www.karolinskadevelopment.com For further information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Hans-Christoffer “HC” Toll, CFO, Karolinska Development AB Phone: +46 70 717 00 41, e-mail: per.aniansson@karolinskadevelopment.com TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of...